Heparin - Market Insights, Competitive Landscape, and Market Forecast - 2032

Heparin Market by Source (Bovine, Porcine, and Others), Route of Administration (Subcutaneous and Intravenous), Application (Coronary Artery Disease, Atrial Fibrillation, Venous Thromboembolism, Renal Impairment, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of cardiovascular disorders and cancer globally, growing demand for whole blood and blood component transfusion and blood donation, and increase in product development activities across the globe.

The heparin market was valued at USD 9,767.61 million in 2024, growing at a CAGR of 8.12% during the forecast period from 2025 to 2032 to reach USD 18,188.09 million by 2032. The global heparin market is propelled by a convergence of factors shaping the pharmaceutical landscape. Firstly, the increasing prevalence of cardiovascular disorders and cancer globally is driving the demand for heparin, as these conditions often require anticoagulation therapy to prevent life-threatening blood clots. Additionally, the growing demand for whole blood and blood component transfusions, especially in surgeries, trauma cases, and oncology treatments, further supports the need for heparin, which is crucial in preventing clot formation during transfusion procedures. Furthermore, the rise in product development activities across the globe, including advancements in low molecular weight heparin (LMWH) and novel formulations, enhances the accessibility and safety of heparin, boosting its overall market growth during the forecasted period from 2025 to 2032.

Heparin Market Dynamics:

According to the World Heart Federation (2024), approximately 60 million population globally were affected by atrial fibrillation. Additionally, as per the same source people with atrial fibrillation are 5X times more likely to suffer a stroke.

Moreover, according to the recent data provided by the British Heart Foundation (2024), globally, around 56 million women and 45 million men were stroke survivors. It was estimated that at least 13 million people worldwide lived with congenital heart disease, with potentially millions more undiagnosed.

Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, affected an estimated 200 million people globally. Approximately 110 million men and 80 million women were affected. Additionally, around 56 million women and 45 million men were stroke survivors.

In the treatment of unstable coronary artery disease (CAD), therapeutic-dose unfractionated heparin has proven effective in reducing adverse ischemic outcomes, including death and myocardial infarction. Additionally, intravenous heparin plays a crucial role in preventing future cardiac events following an episode of unstable CAD. Low-molecular-weight heparin (LMWH), which shares similar antithrombotic properties, offers the advantage of subcutaneous administration and is well-suited for long-term management of cardiovascular patients. This flexibility, combined with its efficacy, has led to a rising global demand for heparin as a vital component of cardiovascular care.

Similarly, cancer patients are often at high risk of developing thromboembolic complications, which necessitates the use of anticoagulants for treatment. For instance, as per the recent data provided by GLOBOCAN (2024), in 2022, globally, the estimated number of new cases of cancer was 20 million and the projections were estimated to increase by 32.6 million by 2045. Chemotherapy and prolonged immobilization during cancer therapy further contribute to this need, as cancer-associated thrombosis is a common side effect. Heparin, an anticoagulant, helps prevent and treat these clots by inhibiting proteins involved in clot formation. This reduces the risk of conditions such as deep vein thrombosis (DVT), pulmonary embolism, and strokes, thus driving the growing demand for heparin in the market across the globe.

Additionally, the growing demand for whole blood and blood component transfusions and donations is significantly boosting the global heparin market, as heparin is essential in preventing clot formation during these processes. This anticoagulant ensures the safe handling of blood products, maintaining fluidity during collection, processing, and transfusion. According to the recent data provided by the World Health Organization (2023), globally, 118.5 million blood donations were collected in 2023, with 40% originating from high-income countries (WHO). The rate of blood donations per 1,000 people varies significantly by income level, further illustrating global disparities in access to blood and blood products. Heparin is vital in the collection and processing of these components, ensuring proper separation of RBCs, plasma, and platelets. As healthcare systems worldwide emphasize safe transfusion practices, the use of heparin in blood management protocols is increasing, driving the demand for heparin products and contributing to the overall growth of the global heparin market.

Furthermore, the heparin market is experiencing rapid growth, fueled by significant advancements in product development, R&D efforts, clinical trials, and regulatory approvals across the globe. For instance, in January 2022, Optimvia and Ginkgo Bioworks announced a partnership to improve the manufacturing efficiency of biosynthetic heparin, an essential medicine currently produced from industrial animal agriculture. Under the partnership, Optimvia seeks to leverage Ginkgo's cell and enzyme engineering platform, as well as its fermentation process development expertise, to rapidly improve the performance of Optimvia's biosynthetic heparin manufacturing technology.

Thus, the factors mentioned above are expected to boost the overall market of heparin across the globe during the forecast period from 2025 to 2032.

However, Potential and fatal side effects associated with the use of heparin and the availability of alternative methods of anticoagulation may hinder the future market of heparin across the globe during the forecasted period.

Heparin Market Segment Analysis:

Heparin Market by Source (Bovine, Porcine, and Others), Route of Administration (Subcutaneous and Intravenous), Application (Coronary Artery Disease, Atrial Fibrillation, Venous Thromboembolism, Renal Impairment, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

The porcine category in the heparin market is estimated to dominate the market with a market share of 87.30% in 2024. Porcine-derived heparin is a major contributor to the growth of the heparin market due to its widespread use in medical treatments and the increasing demand for anticoagulant therapies globally. Heparin, which is primarily extracted from the intestines of pigs, plays a vital role in preventing and treating conditions like deep vein thrombosis, and pulmonary embolism, and in patients undergoing surgeries such as cardiac bypass, dialysis, and organ transplants. The global reliance on porcine-derived heparin stems from its efficacy, established safety profile, and long history of use in both hospital settings and outpatient care. As the number of surgeries and medical procedures requiring anticoagulation therapy rises, particularly with the aging population and increasing prevalence of cardiovascular diseases, the demand for heparin, including porcine-sourced versions, continues to grow.

Additionally, clinicians had substantial experience with porcine heparin, resulting in well-established dosing procedures and monitoring techniques. However, the reliance on a single animal source and country of origin emphasizes the need to diversify the heparin supply chain. Although both bovine and porcine heparin are efficient anticoagulants, their potency varies. Bovine heparin is only proven to be around two-thirds as powerful as swine heparin, which may demand dosage modifications when switching between the two sources, making porcine heparin a preferred choice in terms of potency.

Also, in October 2023, Miratorg, a Russian pork company and a Russian subsidiary of the Van Hessen Group opened the Geparinus factory in the Kursk region. The factory aimed to produce medicinal heparin in its basic form as well as hydrolyzed feed protein. Miratorg stated that Geparinus will process mucosa from both the company's slaughterhouses and other market competitors, and was designed to treat 40,000 tons of mucosa per year, producing 70 tonnes of medicinal heparin.

Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of heparin across the globe.

North America is expected to dominate the overall heparin market:

Among all regions, North America is estimated to hold the largest share of 38.59% in the global heparin market in 2024, growing at a CAGR of 7.62% during the forecast period from 2025 to 2032. This can be attributed to the increasing prevalence of chronic disorders such as cardiovascular diseases, and diabetes, among others. Additionally, the increase in strategic activities among the key market players is further boosting the overall market of heparin across the region. Furthermore, the growing demand for whole blood and blood component transfusions and the increase in cancer cases can further propel the market across the region.

According to the recent data provided by the Centre for Disease Control and Prevention (2024), in 2022, approximately 4.9% of adults have been diagnosed with coronary heart disease.

Additionally, as per the recent data provided by the Centre for Disease Control and Prevention (2024), approximately 12.1 million population in the United States will have atrial fibrillation by 2023.

Additionally, as per the same source each year, over 795,000 individuals in the United States experience a stroke. Of these, approximately 610,000 are first-time or new strokes. Nearly 185,000 strokes, accounting for almost 1 in 4, occur in people who have already had a stroke.

Heparin is widely used as an anticoagulant to prevent and manage complications associated with CVDs, including deep vein thrombosis (DVT), pulmonary embolism (PE), and acute coronary syndrome (ACS). For patients undergoing cardiac surgeries, including coronary artery bypass grafting (CABG) or percutaneous coronary interventions (PCI), heparin is often administered to prevent clot formation during and after the procedure. Heparin's ability to quickly and effectively prevent thrombosis makes it a preferred choice for such high-risk cardiovascular treatments. Additionally, as the incidence of atrial fibrillation (AF) rises a condition that increases the risk of stroke and is commonly linked to cardiovascular diseases there is an increased need for anticoagulation therapy to reduce stroke risk, further boosting the demand for heparin.

Moreover, the increasing use of heparin highlights the rapid adoption and increases product approval across the region, which is expected to drive market growth. For instance, in November 2023, the FDA approved a taurolidine plus heparin (DefenCath(R)) catheter lock solution to reduce catheter-related bloodstream infections in patients receiving maintenance hemodialysis via a central venous catheter (CVC).

Thus, the above-mentioned factors are expected to escalate the market of heparin in the region.

Heparin Market Key Players:

Some of the key market players operating in the heparin market include Pfizer Inc., Dr. Reddy's Laboratories Ltd., Gland Pharma Limited, Sanofi, B. Braun Melsungen AG, Fresenius SE & Co. KGaA, Novartis AG, Baxter, Leo Pharma A/S, Cardinal Health, and others.

Recent Developmental Activities in the Heparin Market:

• In June 2024, InsightRX and Northern Arizona Healthcare (NAH) announced that they had made InsightRX's precision dosing software for heparin therapy available to the pharmacists at Flagstaff Medical Center. NAH anticipated that this move would reduce the time needed to therapeutically dose hospitalized patients with unfractionated heparin, which was expected to enhance patient outcomes by improving the management of blood clot treatment and prevention.
• In February 2024, B. Braun Medical Inc. announced the launch of its new Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL), the fifth product in its portfolio of heparin premixed bags. The launch reaffirmed B. Braun's commitment to improving the security of supply by manufacturing pharmaceuticals in the United States from its Irvine, CA, facility.

Key Takeaways From the Heparin Market Report Study

• Market size analysis for current heparin size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the heparin market.
• Various opportunities available for the other competitors in the heparin market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current heparin market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for heparin market growth in the coming future?

Target Audience Who Can be Benefited From This Heparin Market Report Study

• Heparin product providers
• Research organizations and consulting companies
• Heparin-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in Heparin
• Various end-users who want to know more about the heparin market and the latest technological developments in the heparin market.

Frequently Asked Questions for the Heparin Market:

1. What is heparin?

• Heparin is a polysaccharide used as an injectable anticoagulant to prevent blood clotting in medical treatments. It is effective in managing conditions such as venous thromboembolism and coronary artery disease by reducing the risk of blood clot formation.

2. What is the market for heparin?

• The heparin market was valued at USD 9,767.61 million in 2024, growing at a CAGR of 8.12% during the forecast period from 2025 to 2032 to reach USD 18,188.09 million by 2032.

3. What are the drivers for the global heparin market?

• The global heparin market is propelled by a convergence of factors shaping the pharmaceutical landscape. Firstly, the increasing prevalence of cardiovascular disorders and cancer globally is driving the demand for heparin, as these conditions often require anticoagulation therapy to prevent life-threatening blood clots. Additionally, the growing demand for whole blood and blood component transfusions, especially in surgeries, trauma cases, and oncology treatments, further supports the need for heparin, which is crucial in preventing clot formation during transfusion procedures. Furthermore, the rise in product development activities across the globe, including advancements in low molecular weight heparin (LMWH) and novel formulations, enhances the accessibility and safety of heparin, boosting its overall market growth during the forecasted period from 2025 to 2032.

4. Who are the key players operating in the global heparin market?

• Some of the key market players operating in the heparin are Pfizer Inc., Dr. Reddy's Laboratories Ltd., Gland Pharma Limited, Sanofi, B. Braun Melsungen AG, Fresenius SE & Co. KGaA, Novartis AG, Baxter, Leo Pharma A/S, Cardinal Health, and others.

5. Which region has the highest share in the global heparin market?

• North America is anticipated to dominate the overall heparin market owing to the increasing prevalence of chronic disorders such as cardiovascular diseases, and diabetes, among others. Additionally, the increase in strategic activities among the key market players is further boosting the overall market of heparin across the region. Furthermore, the growing demand for whole blood and blood component transfusions and the increase in cancer cases can further propel the market across the region.